Compare IDCC & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDCC | CYTK |
|---|---|---|
| Founded | 1972 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 7.6B |
| IPO Year | 2007 | 2004 |
| Metric | IDCC | CYTK |
|---|---|---|
| Price | $362.24 | $63.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 19 |
| Target Price | ★ $412.50 | $89.26 |
| AVG Volume (30 Days) | 252.7K | ★ 1.4M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 11.80 | N/A |
| Revenue | ★ $307,404,000.00 | $13,368,000.00 |
| Revenue This Year | N/A | $7.37 |
| Revenue Next Year | $3.38 | $310.19 |
| P/E Ratio | $30.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $195.41 | $29.31 |
| 52 Week High | $412.60 | $70.98 |
| Indicator | IDCC | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 42.97 |
| Support Level | $350.35 | $59.12 |
| Resistance Level | $365.98 | $64.22 |
| Average True Range (ATR) | 12.25 | 2.12 |
| MACD | 1.27 | -0.46 |
| Stochastic Oscillator | 45.29 | 22.37 |
InterDigital Inc is a research and development company focused on wireless, video, Artificial Intelligence, and related technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, out of which the majority is from China.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.